# Anti-amyloid treatment

Source: https://onco.cc/fronts/da-front-anti-amyloid/  
OnCo record `da-front-anti-amyloid` (Front). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Antibodies that lower amyloid plaques in early symptomatic Alzheimer’s disease, with ARIA monitoring.

## Summary

Lecanemab and donanemab are the current US-approved examples. They need amyloid confirmation, infusion capacity, and MRI. They are not indicated for vascular, Lewy body, or frontotemporal dementia as disease-modifying care.

## Fields

- Kind: Front
- Last checked: 2026-09-21
- Tags: dementia-atlas

## Sources

- FDA Leqembi: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval

## Connected records

- drugs: [Donanemab](https://onco.cc/drugs/da-donanemab/), [Lecanemab](https://onco.cc/drugs/da-lecanemab/)
- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)
- technologies: [Anti-amyloid antibodies](https://onco.cc/technologies/da-tech-anti-amyloid-mab/)

---
JSON: https://onco.cc/api/v1/entities/da-front-anti-amyloid.json